Two Blood Pressure-Lowering Peptides From One Gene: Adrenomedullin and PAMP
The adrenomedullin gene produces two distinct blood pressure-lowering peptides — adrenomedullin and PAMP — that work through different mechanisms and may play roles in pregnancy and cancer.
Quick Facts
What This Study Found
Adrenomedullin and PAMP are co-produced from the same gene but lower blood pressure through distinct mechanisms (direct vascular vs. neural), and are expressed in diverse tissues with roles in cardiovascular, reproductive, and cancer biology.
Key Numbers
How They Did This
Review article summarizing the biology, tissue distribution, cardiovascular effects, and clinical significance of adrenomedullin and PAMP, including their roles in pregnancy and cancer.
Why This Research Matters
These peptides represent a sophisticated blood pressure control system. Understanding their distinct mechanisms could lead to novel treatments for hypertension, heart failure, and potentially cancer.
The Bigger Picture
The cardiovascular system uses multiple peptide signaling systems to fine-tune blood pressure. Adrenomedullin and PAMP add another layer of control, and their involvement in cancer and pregnancy suggests they regulate tissue growth and blood supply formation.
What This Study Doesn't Tell Us
Review based on early research; many proposed roles were not yet confirmed in clinical studies. The relative importance of AM vs. PAMP in human physiology was not fully established.
Questions This Raises
- ?Could adrenomedullin analogs be developed as blood pressure medications?
- ?What role do these peptides play in cancer angiogenesis?
- ?How do AM and PAMP levels change throughout pregnancy?
Trust & Context
- Key Stat:
- 2 peptides, 2 mechanisms Adrenomedullin lowers blood pressure directly on vessels while PAMP works through the nervous system — both from the same gene
- Evidence Grade:
- Moderate evidence from a review of emerging research. Individual findings range from strong (cardiovascular effects) to preliminary (cancer and reproductive roles).
- Study Age:
- Published in 1998. Adrenomedullin has since become a recognized biomarker and therapeutic target, with MR-proADM used clinically for sepsis prognosis.
- Original Title:
- Proadrenomedullin-derived peptides.
- Published In:
- Frontiers in neuroendocrinology, 19(2), 100-27 (1998)
- Authors:
- Samson, W K
- Database ID:
- RPEP-00491
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What is adrenomedullin?
Adrenomedullin is a peptide hormone produced by blood vessels and many other tissues. It powerfully relaxes blood vessels and lowers blood pressure, and its blood levels are elevated in heart failure, indicating the body is trying to compensate.
Why does one gene make two different peptides?
Many genes produce a long precursor protein that gets cut into multiple active peptides. This is an efficient way for the body to generate related but distinct signaling molecules from a single genetic instruction.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00491APA
Samson, W K. (1998). Proadrenomedullin-derived peptides.. Frontiers in neuroendocrinology, 19(2), 100-27.
MLA
Samson, W K. "Proadrenomedullin-derived peptides.." Frontiers in neuroendocrinology, 1998.
RethinkPeptides
RethinkPeptides Research Database. "Proadrenomedullin-derived peptides." RPEP-00491. Retrieved from https://rethinkpeptides.com/research/samson-1998-proadrenomedullinderived-peptides
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.